Abstracts tagged "prescribing trends"

Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Ting-Chun Yeh¹, Yolaine Jeune-Smith ¹, Eli Phillips ¹, Ajeet Gajra ¹ and Bruce Feinberg ¹, ¹Cardinal Health Specialty Solutions, Dublin, OH
Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…
Abstract Number: 1917 • 2018 ACR/ARHP Annual Meeting
Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
Yvonne C. Lee¹, Bing Lu², Hongshu Guan³, Jeffrey Greenberg⁴, Joel Kremer⁵ and Daniel Solomon⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Experts have implicated physician prescribing rates as a contributing factor to the opioid crisis. However, little is known about heterogeneity in these patterns and…
Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting
Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study
Elena Nikiphorou¹, Désirée van der Heijde², Sam Norton³, Robert B.M. Landewé⁴, Anna Moltó⁵, Maxime Dougados⁶, Filip van Den Bosch⁷ and Sofia Ramiro⁸, ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Rheumatology, King´s College London, London, United Kingdom, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Paris Descartes University, Paris, France, ⁶Paris-Descartes University,, Paris, France, ⁷Rheumatology, Ghent University Hospital, Gent, Belgium, ⁸Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…
Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…
Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting
Variation in the Prescribing Practices of Biologic Dmards
Heather O. Tory¹, Josephine A. Awosogba², Amish J. Dave², Jonathan S. Coblyn², Daniel H. Solomon² and Sonali P. Desai², ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…
Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Doquyen H. Huynh¹, Carol J. Etzel^2,3, Vanessa Cox⁴, Philip J. Mease⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²PO Box 786, Corrona, LLC., Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴CORRONA, Inc, Southborough, MA, ⁵CORRONA, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…